These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 26384430)

  • 1. CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene.
    Liu YC; Chang PY; Chao CC
    Nucleic Acids Res; 2015 Dec; 43(22):10760-81. PubMed ID: 26384430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of CITED2 using short-hairpin RNA sensitizes cancer cells to cisplatin through stabilization of p53 and enhancement of p53-dependent apoptosis.
    Wu ZZ; Sun NK; Chao CC
    J Cell Physiol; 2011 Sep; 226(9):2415-28. PubMed ID: 21660965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MZF1 possesses a repressively regulatory function in ERCC1 expression.
    Yan QW; Reed E; Zhong XS; Thornton K; Guo Y; Yu JJ
    Biochem Pharmacol; 2006 Mar; 71(6):761-71. PubMed ID: 16426580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
    Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
    Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of EBAF in the heart with ventricular septal defects and its regulation by histone acetyltransferase p300 and transcription factors smad2 and cited2.
    Su D; Li Q; Guan L; Gao X; Zhang H; Dandan E; Zhang L; Ma X
    Biochim Biophys Acta; 2013 Dec; 1832(12):2145-52. PubMed ID: 23899608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CITED2 controls the hypoxic signaling by snatching p300 from the two distinct activation domains of HIF-1α.
    Yoon H; Lim JH; Cho CH; Huang LE; Park JW
    Biochim Biophys Acta; 2011 Dec; 1813(12):2008-16. PubMed ID: 21925214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CITED2 affects leukemic cell survival by interfering with p53 activation.
    Mattes K; Berger G; Geugien M; Vellenga E; Schepers H
    Cell Death Dis; 2017 Oct; 8(10):e3132. PubMed ID: 29072699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
    Du P; Zhang X; Liu H; Chen L
    DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).
    Tsai MS; Weng SH; Kuo YH; Chiu YF; Lin YW
    Mol Pharmacol; 2011 Jul; 80(1):136-46. PubMed ID: 21493726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of DNA repair gene expression in human cancer cell lines.
    McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR
    J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR‑138‑5p modulates the expression of excision repair cross‑complementing proteins ERCC1 and ERCC4, and regulates the sensitivity of gastric cancer cells to cisplatin.
    Ning J; Jiao Y; Xie X; Deng X; Zhang Y; Yang Y; Zhao C; Wang H; Gu K
    Oncol Rep; 2019 Feb; 41(2):1131-1139. PubMed ID: 30535472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.
    Chang IY; Kim MH; Kim HB; Lee DY; Kim SH; Kim HY; You HJ
    Biochem Biophys Res Commun; 2005 Feb; 327(1):225-33. PubMed ID: 15629453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cited2 modulates TGF-beta-mediated upregulation of MMP9.
    Chou YT; Wang H; Chen Y; Danielpour D; Yang YC
    Oncogene; 2006 Sep; 25(40):5547-60. PubMed ID: 16619037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance.
    Li W; Melton DW
    Oncogene; 2012 May; 31(19):2412-22. PubMed ID: 21996734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients.
    Lai TC; Chow KC; Fang HY; Cho HC; Chen CY; Lin TY; Chiang IP; Ho SP
    Oncol Rep; 2011 May; 25(5):1243-51. PubMed ID: 21327329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for CITED2, a CBP/p300 interacting protein, in colon cancer cell invasion.
    Bai L; Merchant JL
    FEBS Lett; 2007 Dec; 581(30):5904-10. PubMed ID: 18054336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation.
    Thomas MC; Chiang CM
    Mol Cell; 2005 Jan; 17(2):251-64. PubMed ID: 15664194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells.
    Sun Y; Li T; Ma K; Tian Z; Zhu Y; Chen F; Hu G
    Cancer Invest; 2009 Nov; 27(9):891-7. PubMed ID: 19832035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-transcriptional control of Cited2 by transforming growth factor beta. Regulation via Smads and Cited2 coding region.
    Chou YT; Yang YC
    J Biol Chem; 2006 Jul; 281(27):18451-62. PubMed ID: 16675452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.